Sort   by:  
 Page size 
ProteomicsMultiplexed drug-based selection and counterselection genetic manipulations in Drosophila
We describe a drug-based, genetic platform consisting of four selection and two counterselection markers eliminating the need to screen for transgenic progeny. These markers work reliably individually, or in combination, to produce specific genetic outcomes.We perform immunoprecipitation followed by...
ORGANISM(S): Drosophila melanogaster (Fruit fly) 
2022-02-17 | PXD026579 | Pride
Selection Drosophila P[acman] 
ProteomicsTestis-specific serine kinase 3 is required for sperm morphogenesis and male fertility
TSSK3 is expressed in elongating sperm and localizes to the sperm tail. To define the essential roles of TSSK3 in vivo and elucidate the mechanisms causing the phenotype, we conducted phosphoproteomics using purified germ cells from Tssk3 HET and KO testes.
ORGANISM(S): Mus musculus (Mouse) 
2023-11-21 | PXD038012 | Pride
Proteomics Oligoteratozoospermia Knockout mouse Teratozoospermia Oligozoospermia 
ProteomicsThe Role of FASN in bladder cancer
To dissect the mechanistic interplay between fatty acid metabolism and cigarette smoke–induced signaling in bladder cancer, we employed a proteomics analysis xenograft tumors derived from the UMUC3 with either stable FASN knockdown (KD) or control shRNA, with and without cigarette smoke. We performe...
ORGANISM(S): Mus musculus (Mouse) Homo sapiens (Human) 
2026-06-15 | PXD068785 | Pride
Proteomics Fasn Cigarette smoke Bladder cancer 
ProteomicsHistone serotonylation regulates ependymoma tumorigenesis through neurodevelopmental pathways
Bidirectional communication between tumors and neurons has emerged as a key facet of the tumor microenvironment that drives malignancy. Another hallmark feature of cancer is epigenomic dysregulation, where alterations in gene expression influences cell states and interactions with the tumor microenv...
ORGANISM(S): Mus musculus (Mouse) 
2024-09-09 | PXD048170 | Pride
Epigenetic regulation Zfta-rela ependymoma Cancer neuroscience Developmental transcription factor 
ProteomicsEffect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells
Patient-derived secondary AML cells were treated with 100 nM of SY-5609 for 24 hours, 100 nM of FHD-286 for 48 hours, or 20 µM of Tasquinimod for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD053548 | Pride
Secondary aml Sndx-50469 Tasquinimod Cdk7 inhibitor Fhd-286 
ProteomicsEffect of CDK7 inhibitor on protein expression alterations in cultured secondary AML HEL92.1.7 cells
HEL92.1.7 cells in exponential growth phase were treated with 100 nM of SY-5609 for 24 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a CDK7 inhibitor in secondary AML cells.
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD053572 | Pride
Secondary aml Cdk7 inhibitor C-myc 
ProteomicsProject title: Effect of FHD-286 or BRG1/BRM degrader AU15330 on protein expressions in MLL1-rearranged AML cells
MOLM13 cells and patient-derived de novo AML cells with MLL1 rearrangement were treated with 100 nM of FHD-286 or 100 nM of AU15330, a dual BRG1/BRM protein degrader for 48 hours. The goal was to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitor...
ORGANISM(S): Homo sapiens (Human) 
2025-04-28 | PXD055994 | Pride
Fhd-286 Au15330 Protac Chromatin 
ProteomicsDetermination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in patient-derived mutant NPM1 and FLT-ITD-expressing AML cells
We treated patient-derived mutant NPM1-and FLT3-ITD expressing AML cells with a chromatin remodeling inhibitor, FHD-286, at a dose of 100 nM, for 48 hours to determine FHD-286-mediated changes to the AML proteome.
ORGANISM(S): Homo sapiens (Human) 
2025-05-06 | PXD047967 | Pride
Chromatin remodelers Mutant npm1 Aml Fhd-286 
ProteomicsEffect of BET inhibitor, mivebresib, dactolisib or LCL-161 on protein expressions in AML cells with MECOM rearrangement and high expression of EVI1
Patient-derived AML194 (acute myeloid leukemia with inv3(q21;q26.2)) cells were treated in duplicate with 0 nM or 500 nM of mivebresib, 500 nM of dual PI3K/mTOR inhibitor dactolisib or 1000 nM of IAP antagonist LCL-161 for 24 hours to determine the global protein expression alterations that correlat...
ORGANISM(S): Homo sapiens (Human) 
2026-02-16 | PXD063413 | Pride
Bet inhibitor Mecom Evi1 Mtor Aml 
ProteomicsEffect of SMARCA2/SMARCA4 inhibitor, FHD-286, on protein expression alterations in cultured cell line or patient-derived AML cells with MECOM rearrangement and expression of EVI1
Patient-derived AML191 (acute myeloid leukemia with inv3(q21;q26.2)), -7) cells were treated in duplicate with 100 nM of FHD-286 for 0, 8, 16, 24 and 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment ...
ORGANISM(S): Homo sapiens (Human) 
2026-01-23 | PXD059059 | Pride
Mecom Brg1 Evi1 Fhd-286 Aml 
Sort   by:  
 Page size